Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss

Pre- and Posttransplant IgA Anti-Fab Antibodies to Predict Long-term Kidney Graft Survival

“…Accordingly, we observed a significant improved graft survival not only in patients with high pretransplant levels of IgA anti-Fab antibodies (P ¼ .02), but also in patients with high posttransplant (days 7 and 30) levels of these autoantibodies (P ¼ .005 and P ¼ .003, respectively). However, in contrast with our results, some previous studies did not show any correlation between pretransplant contents of IgA anti-Fab antibodies and kidney graft survival [16,17].…”

Peritransplant Soluble CD30 as a Risk Factor for Slow Kidney Allograft Function, Early Acute Rejection, Worse Long-Term Allograft Function, and Patients’ Survival

“…This finding indirectly confirms existing data [9, 29, 40] that T cell activation marker sCD30 is a good indicator of immunological risk apart of antibody sensitization. Our results also imply that pretransplant sCD30 can help in risk stratification of patients without classical signs of sensitization that was suggested earlier by other authors [43]. Pretransplant sCD30 has high specificity and sensitivity in predicting early AR in the recipients of deceased-donor graft at a threshold of 70.6 U/mL in our study.…”

Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant

“…Rodriguez et al (43) demonstrated that the presence of pre-transplant anti-HLA Class I antibodies was associated with decreased kidney graft survival, primarily during the first year post-transplantation. On the other hand, positive PRA seemed not to influence sCD30 levels in patients with ARE until 14 d. However, it is necessary to realize further tests to assess the influence of PRA in sCD30 levels, because our number of patients with ARE is small.…”